Sign up
Log in
RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics
Share
Listen to the news
RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics
  • RA Capital Management filed a Form 3 showing beneficial ownership of 25 million Inhibikase Therapeutics common shares.
  • The filing lists RA Capital as a 10% owner, with the position reported as indirect ownership.
  • The event date was July 10, 2026; the statement was signed and dated July 17, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001231919-26-000769), on July 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.